Biocrosmo

BioCrosmo is a South Korean biotechnology company specializing in the development of advanced drug delivery systems designed to overcome biological barriers. The company's core technology, the Crosmo platform, utilizes proprietary peptide-based molecules to facilitate the delivery of macromolecular therapeutics, such as proteins and antibodies, across the blood-brain barrier (BBB) and into target cells. BioCrosmo is primarily focused on treating central nervous system (CNS) disorders, including Alzheimer's and Parkinson's diseases, where traditional drug delivery remains a significant challenge. By enhancing the bioavailability and precision of large-molecule drugs, the company aims to provide more effective treatments for neurodegenerative and metabolic conditions. The platform's versatility also allows for potential applications in oncology and metabolic diseases like obesity.